AI companies face the same core IPO risks as other issuers—uncertain valuation, business execution, governance, share supply and market conditions—with additional exposure to fast-changing technology, customer demand and high expectations. A lockup expiration can make more shares eligible for sale, but it does not require holders to sell or predict what a stock will do. To assess a specific offering, read its prospectus and later SEC filings: the actual terms, share counts and risk disclosures matter more than general rules of thumb.
What makes an AI IPO risky?
An IPO is not a guarantee that a company will grow into its valuation or that investors will be able to sell shares at a desired price. AI exposure does not remove ordinary market, liquidity, execution or governance risks. It can also make expectations about future growth especially important to how investors value a company.
Valuation and expectations
In its 2026 Form 10-Q, Cerebras Systems warned that its stock price could fluctuate significantly with broad equity and semiconductor-market performance, company financial and operating metrics, customer or partnership developments, analyst expectations, rumors, competitor announcements, regulation, litigation, personnel changes and anticipated share sales. It also said that high valuations and speculation about AI’s future growth and performance had contributed to volatility in AI and technology stocks. This is an issuer’s risk disclosure—not evidence that a particular AI IPO is overvalued or that its share price will fall.
For an offering, compare the proposed price range and implied equity value with audited results, the fully diluted share count, margins, cash needs and the growth assumptions embedded in the valuation. Keep historical results distinct from management projections, private-market valuations and media estimates.
The Tool Desk
Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →#1 Best Overall
Business, customers and costs
AI businesses can depend on a small number of customers, partners, cloud providers or suppliers. Cerebras specifically identified possible adverse changes in its relationships with OpenAI or AWS and reduced purchases by named customers and partners as factors that could affect its stock. Those are Cerebras-specific disclosures, not risks that can automatically be assigned to another AI company.
- Check customer concentration, contract duration, renewal and termination provisions, and whether demand depends on a few buyers.
- Review reliance on cloud providers, suppliers, compute capacity and power, including whether the company can serve demand at a sustainable cost.
- Assess competition, product or model differentiation, capital requirements and whether the company’s stated plans depend on continued access to financing.
For OpenAI, the Associated Press reported on June 8, 2026, that the company faced competition from Anthropic and Google and high infrastructure costs. AP also reported that OpenAI had not publicly disclosed how much money it was making or when it expected to be profitable. Those are dated media reports, not audited financial facts; a public filing, if available, is the more appropriate source for current financial statements and issuer-identified risks.
Governance, dilution and share count
The number of shares sold in an IPO is not the same as the company’s fully diluted share count, the public float or the share of voting power available to public investors. Cerebras disclosed three common-stock classes after its IPO. Its Class B shares carried 20 votes per share versus one vote per Class A share. Based on beneficial ownership as of March 31, 2026, Class B holders held approximately 99.2% of post-IPO voting power, according to the company’s 2026 Form 10-Q. Cerebras warned that its multi-class structure concentrated control and could limit Class A holders’ influence.
Rank #2
Read the prospectus for the voting rights and conversion triggers attached to each class, board and shareholder rights, related-party arrangements, and control provisions. Also distinguish authorized shares, shares sold by the company, shares sold by existing holders, shares outstanding after the offering and shares reserved for options or restricted stock units (RSUs). Options, RSUs, registration rights and future sales can affect dilution or the supply of shares available to trade.
What happens when an IPO lockup expires?
A lockup is a contractual restriction that limits specified holders’ ability to sell or transfer specified securities for a stated period. The prospectus and related underwriting arrangements define the terms. When a restriction ends, covered shares may become eligible for sale, subject to any other applicable restrictions; expiration does not itself cause a sale.
Read the specific agreement, not a typical timetable
There is no universal expiration date or single lockup structure to apply to every AI IPO. Check which holders and securities are covered, when the period starts and ends, permitted transfers, tax-related sell-to-cover provisions, staged releases, underwriter waiver authority and separate registration rights. An underwriter’s discretion or an exception can change when some shares become eligible to trade.
Rank #3
Cerebras’s 2026 Form 10-Q described lockups and market standoff provisions ending at the earlier of 6:00 a.m. Eastern Time on the second trading day after the release of earnings for the quarter ended September 30, 2026, or 180 days after the prospectus date. The terms included customary exceptions and possible early releases. The filing estimated that up to approximately 171.1 million shares could be released during the lockup period under those provisions. These are Cerebras-specific estimates and terms, not a standard for other IPOs; later filings are needed to confirm actual releases and updated figures.
Eligibility to sell is not a sale
When a lockup expires, insiders and other large holders may sell, retain shares or sell only some of their holdings. If many shares are sold—or the market expects that they may be—the additional potential supply can weigh on price or make it harder to trade at a preferred time and price. Cerebras explicitly identified both actual and perceived sales as possible risks in its Form 10-Q. Neither a lockup expiration nor a large number of newly eligible shares establishes that selling will occur or that the stock will decline.
Recommended Free Tools
Cerebras also estimated that up to approximately 1.2 million shares might be sold on or around August 18, 2026, for tax withholding on RSUs. That date has passed; the estimate does not establish what actually happened. Use subsequent company filings for any reported sales or revised share counts.
Why are AI stocks volatile?
AI stocks can move sharply when investors revise expectations about growth, profitability, competition or the pace of adoption. In the Cerebras filing, the company cited changes in its operating metrics, customer and partnership developments, analyst expectations, market conditions, rumors, competitor announcements, regulation, litigation, personnel changes and anticipated share sales among factors that could affect its price. These are possible drivers, not a formula for predicting the direction or size of a price move.
Volatility can reflect a shift in expectations as well as a change in reported business performance. The Cerebras disclosure states that extreme price and trading-volume changes have affected semiconductor, AI and technology stocks, and describes speculation about future industry growth and performance as one contributor. That does not show that every AI stock is unusually volatile at all times, or that volatility guarantees a loss.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.How to compare AI IPOs using public filings
Use the prospectus, any amendments, the final offering documents and subsequent SEC filings for company-specific claims. Compare equivalent measures and label what is unknown rather than filling gaps with estimates from private valuations or secondary reporting.
Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Fix the driver behind crashes, sound loss and screen glitches3Repair Windows errors before they cause bigger problems| Area | What to examine | Why it matters |
|---|---|---|
| Price and valuation | Proposed price range, implied equity value, fully diluted share count and the assumptions behind expected growth or margins. | A share price alone does not show whether the valuation is supported by the company’s financial profile. |
| Financial quality | Audited revenue and growth, gross margin, cash burn, capital needs, debt, stock-based compensation, customer concentration and the distinction between results and projections. | Growth does not by itself establish that a business can fund operations or become profitable. |
| Business durability | Customer and cloud-provider dependence, contract terms, renewal exposure, compute and power costs, ability to meet demand, competition and product or model differentiation. | Demand can be vulnerable to a few relationships, rising costs or competitive changes. |
| Share supply and liquidity | Primary shares sold by the company, secondary shares sold by existing holders, expected public float, insider ownership, lockup terms and exceptions, registration rights, options, RSUs and staged release dates. | These measures help distinguish the number of shares outstanding from the shares initially available to trade and those that may become eligible later. |
| Governance | Voting ratios, board structure, shareholder rights, related-party arrangements, control provisions and conversion triggers. | Economic ownership and voting influence can differ. |
| Use of proceeds and execution | How the company says it will use IPO proceeds, whether those funds address operating and capital requirements, and the risks it identifies to executing its plans. | An offering’s stated purpose should be assessed against the company’s funding needs and disclosed execution risks. |
| Evidence and uncertainty | Separate audited historical data, issuer estimates, media reporting, private-market valuations and unpriced or confidential draft filings. | These sources do not have the same status or evidentiary weight. |
What a confidential IPO filing does—and does not—tell you
A confidential draft S-1 is an early step in the process, not a completed public offering, a set price or a guarantee that a listing will occur. Details can change as a registration statement is reviewed and amended.
Anthropic: June 1, 2026 announcement
Anthropic announced that it had confidentially submitted a draft registration statement on Form S-1 to the SEC for a proposed IPO. The company said the offering depended on SEC review, market conditions and other factors, and that the number of shares and price had not been set. It also said the announcement was not an offer to sell securities or a solicitation to buy them. The announcement describes a proposed offering as of June 1, 2026; it does not establish a completed IPO or later offering terms.
OpenAI: June 8, 2026 reporting
The Associated Press reported on June 8, 2026, that OpenAI had confidentially filed preliminary paperwork and had not decided on a public timeline. AP quoted the company as saying, “We have not decided on timing yet; it may be a while because there are things we want to do that are likely easier as a private company.” This is dated reporting, not a current prospectus or confirmation of a listing. A confidential filing and a public registration statement are different process stages; the cited report alone does not establish whether the company later filed publicly, priced shares or completed an offering.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
